Back to results
US 11,883,386 B2Granted
Prolyl hydroxylase inhibitors and methods of use
AssigneeAkebia Therapeutics, Inc.
InventorsRichard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D Greis, Angelique Sun Boyer, Namal C. Warshakoon
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Claims5
A process for preparing a compound having the formula:
- comprising:
- (a) reacting a 4-chlorophenyl boronic acid:
- with methyl 4-bromo-2-methoxybenzoate:
- in the presence of a catalyst to form 4′-chloro-3-methoxy-biphenyl-4-carboxylic acid methyl ester:
- (b) reacting 4′-chloro-3-methoxy-biphenyl-4-carboxylic acid methyl ester obtained from step (a) with lithium hydroxide to form 4′-chloro-3-methoxy-biphenyl-4-carboxylic acid:
- and
- (c) reacting 4′-chloro-3-methoxy-biphenyl-4-carboxylic acid obtained from step (b) with glycine ethyl ester, in the presence of coupling agents to form [(4′-chloro-3-methoxy-biphenyl-4-carbonyl)-amino]-acetic acid ethyl ester:
4 more elements
Dependencies are inferred from the claim text.